Richard Daly - curasan AG Insider

CUR -- Germany Stock  

EUR 0.95  0.012  1.25%

  CEO
Mr. Richard J. Daly is Chairman of the Board President Chief Executive Officer of the company. He has over 25 years of commercial pharmaceutical experience working in positions of progressive responsibility in sales marketing and operations. From November 2015 until February 2016 Mr. Daly was a managing partner at Ravine Rock Partners LLC a biopharmaceutical consulting company. Prior to that from August 2013 until November 2014 Mr. Daly was the President of U.S. Diabetes a subsidiary of AstraZeneca Pharmaceutical LP. From October 2011 until November 2012 Mr. Daly was a founding partner board member and investor in SagePath Partners LLC a commercial outsourcing provider to the pharmaceutical industry. Between July 2008 and October 2011 Mr. Daly was executive vice president of North and South America for Takeda NA the north American subsidiary of Takeda Pharmaceuticals . Since June 2015 Mr. Daly has served on the board of directors and on the Compensation and Commercial Committees for Synergy Pharmaceuticals . Since February 2015 Mr. Daly has also served on the board of directors and on the Compensation Committee of Catalyst Pharmaceuticals
Age: 61  CEO Since 2016  MBA    
49 6027 40 900 51  http://www.curasan.de
Daly holds a BS in Microbiology from The University of Notre Dame and an MBA from Northwestern University Kellogg Graduate School of Management.

Richard Daly Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (13.09) % which means that it has lost $13.09 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (42.32) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 265 K in total debt with debt to equity ratio (D/E) of 2.6 implying the company greatly relies on financing operations through barroing. curasan AG has Current Ratio of 2.1 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 1 records

CEO Since

Liam CondonBayer Aktiengesellschaft
N/A

Entity Summary

curasan AG develops, produces, and markets biomaterials and medical devices for bone and tissue regeneration worldwide. The company was founded in 1988 and is based in Kleinostheim, Germany. curasan AG operates under Biotechnology classification in Germany and traded on Frankfurt Stock Exchange. It employs 30 people.curasan AG (CUR) is traded on Frankfurt Stock Exchange in Germany. It is located in Lindigstrasse 4 and employs 30 people.

curasan AG Leadership Team

William Oldaker, Independent Director
David Castaneda, IR Contact
Stanley Westreich, Independent Director
Karl Johe, Chairman of the Board, Chief Scientific Officer
Scott Ogilvie, Independent Director
Catherine Sohn, Director
Richard Garr, President CEO, General Counsel, Director
Richard Daly, President CEO
Sandford Smith, Director
Jonathan Jones, CFO

Stock Performance Indicators

Did you try this?

Run Price Transformation Now
   

Price Transformation

Use Price Transformation models to analyze depth of different equity instruments across global markets
All  Next Launch Price Transformation

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for curasan AG and Fielmann AG. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">